<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:08:02Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6028965" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:6028965</identifier><datestamp>2018-07-05</datestamp><setSpec>jbc</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Biol. Chem</journal-id>
      <journal-id journal-id-type="hwp">jbc</journal-id>
      <journal-id journal-id-type="pmc">jbc</journal-id>
      <journal-id journal-id-type="publisher-id">JBC</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Biological Chemistry</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0021-9258</issn>
      <issn pub-type="epub">1083-351X</issn>
      <publisher>
        <publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name>
        <publisher-loc>11200 Rockville Pike, Suite 302, Rockville, MD 20852-3110, U.S.A.</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC6028965</article-id>
      <article-id pub-id-type="pmcid">PMC6028965</article-id>
      <article-id pub-id-type="pmc-uid">6028965</article-id>
      <article-id pub-id-type="pmid">29748387</article-id>
      <article-id pub-id-type="pmid">29748387</article-id>
      <article-id pub-id-type="publisher-id">RA118.002817</article-id>
      <article-id pub-id-type="doi">10.1074/jbc.RA118.002817</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Protein Structure and Folding</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Mechanism of vaccinia viral protein B14âmediated inhibition of IÎºB kinase Î² activation</article-title>
        <alt-title alt-title-type="short">B14 inhibits IKKÎ² activation</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5554-6540</contrib-id>
          <name>
            <surname>Tang</surname>
            <given-names>Qingyu</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chakraborty</surname>
            <given-names>Sayan</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4939-5982</contrib-id>
          <name>
            <surname>Xu</surname>
            <given-names>Guozhou</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
          <xref ref-type="corresp" rid="cor1">
            <sup>1</sup>
          </xref>
        </contrib>
        <aff id="aff1">From the Department of Molecular and Structural Biochemistry, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, North Carolina 27695</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1"><label>1</label> To whom correspondence should be addressed. Tel.:
<phone>919-515-0835</phone>; E-mail: <email>gxu3@ncsu.edu</email>.</corresp>
        <fn fn-type="edited-by">
          <p>Edited by Luke O'Neill</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>29</day>
        <month>6</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>10</day>
        <month>5</month>
        <year>2018</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>10</day>
        <month>5</month>
        <year>2018</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
      <volume>293</volume>
      <issue>26</issue>
      <fpage>10344</fpage>
      <lpage>10352</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>3</month>
          <year>2018</year>
        </date>
        <date date-type="rev-recd">
          <day>3</day>
          <month>5</month>
          <year>2018</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© 2018 Tang et al.</copyright-statement>
        <copyright-year>2018</copyright-year>
        <copyright-holder>Tang et al.</copyright-holder>
        <license>
          <license-p>Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.</license-p>
        </license>
        <license license-type="open-access">
          <license-p><italic>Author's Choice</italic>âFinal version free via <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">Creative Commons CC-BY license</ext-link>.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zbc02618010344.pdf"/>
      <abstract>
        <p>Activation of IÎºB kinase Î² (IKKÎ²) is a central event in the NF-ÎºBâmediated canonical pro-inflammatory pathway. Numerous studies have reported that oligomerization-mediated trans autophosphorylation of IKKÎ² is indispensable for its phosphorylation, leading to its activation and IKKÎ²-mediated phosphorylation of substrates such as IÎºB proteins. Moreover, IKKÎ²'s interaction with the NF-ÎºB essential modifier (NEMO) is necessary for IKKÎ² activation. Interestingly, some viruses encode virulence factors that target IKKÎ² to inhibit NF-ÎºBâmediated antiviral immune responses. One of these factors is the vaccinia viral protein B14, which directly interacts with and inhibits IKKÎ². Here we mapped the interaction interface on the B14 and IKKÎ² proteins. We observed that B14 binds to the junction of the kinase domain (KD) and scaffold and dimerization domain (SDD) of IKKÎ². Molecular docking analyses identified key interface residues in both IKKÎ² and B14 that were further confirmed by mutational studies to promote binding of the two proteins. During trans autophosphorylation of protein kinases in the IKK complex, the activation segments of neighboring kinases need to transiently interact with each other's active sites, and we found that the B14âIKKÎ² interaction sterically hinders direct contact between the kinase domains of IKKÎ² in the IKK complex, containing IKKÎ², IKKÎ±, and NEMO in human cells. We conclude that binding of B14 to IKKÎ² prevents IKKÎ² trans autophosphorylation and activation, thereby inhibiting NF-ÎºB signaling. Our study provides critical structural and mechanistic information for the design of potential therapeutic agents to target IKKÎ² activation for the management of inflammatory disorders.</p>
      </abstract>
      <kwd-group>
        <kwd>molecular docking</kwd>
        <kwd>autophosphorylation</kwd>
        <kwd>protein kinase</kwd>
        <kwd>virus</kwd>
        <kwd>inhibition mechanism</kwd>
        <kwd>B14</kwd>
        <kwd>IKKÎ²</kwd>
        <kwd>protein kinase</kwd>
        <kwd>trans autophosphorylation</kwd>
        <kwd>vaccinia virus</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="award1">
          <funding-source>
            <institution-wrap>
              <institution>HHS NIH National Institute of Allergy and Infectious Diseases (NIAID)
</institution>
              <institution-id institution-id-type="open-funder-registry">10.13039/100000060</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>5R01AI118769</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body><sec sec-type="intro"><title>Introduction</title><p>The inhibitor of ÎºB kinase (IKK)<xref ref-type="fn" rid="FN1"><sup>2</sup></xref> complex plays a central role in regulating the activation of NF-ÎºB transcription factors, which are the master regulators of a variety of cellular processes, particularly immune and inflammatory responses (<xref rid="B1" ref-type="bibr">1</xref>). Although many different inducers activate NF-ÎºB, most of the signaling pathways converge on activation of IKK (<xref rid="B2" ref-type="bibr">2</xref>). IKK is a large protein complex that comprises three major subunits, the kinase subunits IKKÎ± (IKK1) and IKKÎ² (IKK2) and a regulatory subunit known as NF-ÎºB essential modifier (NEMO, also called IKKÎ³). IKKÎ² harbors an N-terminal kinase domain (KD), an ubiquitin-like domain (ULD), a scaffold and dimerization domain (SDD), and a C-terminal NEMO-binding domain (NBD). It contributes to the majority of the IÎºB kinase activity of IKK and plays a dominant role in the canonical NF-ÎºB pathway by phosphorylating IÎºBÎ±. IKKÎ± shares more than 50% sequence identity with IKKÎ² and plays an indispensable role in the noncanonical NF-ÎºB pathway (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>).</p><p>The main substrates of IKK are the IÎºB family of proteins, which are the inhibitory proteins of NF-ÎºB (<xref rid="B5" ref-type="bibr">5</xref>). There are at least nine IÎºB members in the human genome, three of which (IÎºBÎ±, IÎºBÎ², and IÎºBÏµ) are classical IÎºB proteins functioning as NF-ÎºB inhibitors (<xref rid="B6" ref-type="bibr">6</xref>). The most extensively studied IÎºB member, IÎºBÎ±, contains two serine residues in the destruction motif consensus DSGÏ<italic>X</italic>S (Ï stands for hydrophobic residue, <italic>X</italic> is any residue) in its N-terminal region. These two serine residues serve as the IKKÎ² phosphorylation sites. The doubly phosphorylated destruction motif is then recognized by the Î²-TrCPâSCF ubiquitin ligase for subsequent ubiquitination and degradation. After degradation of IÎºBÎ±, NF-ÎºB is then released into the nucleus to regulate gene transcription (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>).</p><p>Since its discovery in 1996, the function of the IKK complex has been under intensive investigation. However, its mechanism of activation remains elusive. In response to upstream signaling cues such as pro-inflammatory stimuli, the activation segments of IKKÎ² are phosphorylated at Ser-177 and Ser-181 (<xref rid="B7" ref-type="bibr">7</xref><xref ref-type="bibr" rid="B8">â</xref><xref rid="B9" ref-type="bibr">9</xref>). In mouse embryonic fibroblasts, some upstream kinases, such as transforming growth factor Î²âactivated kinase 1 (TAK1), have been shown to be required for IKKÎ² activation. However, TAK1 only phosphorylates IKKÎ² at Ser-177, which is a priming event that enables IKKÎ² to activate itself by phosphorylating Ser-181 (<xref rid="B10" ref-type="bibr">10</xref>). Other lines of evidence have pointed out that oligomerization-mediated trans autoactivation is required for IKKÎ² activation. It has been found that the overexpressed and reconstituted IKK complex is active (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>) and that binding to different types of poly-ubiquitin chains via NEMO can activate the IKK (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Indeed, in NEMO knockout cells, IKK activity is completely abolished (<xref rid="B15" ref-type="bibr">15</xref>). It is possible that activation of IKKÎ² requires its interaction with NEMO, which, in turn, probably facilitates its oligomerization and trans autophosphorylation events (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Our previous structural studies of IKKÎ² have indicated that the kinase domains in the IKKÎ² dimer face away from each other so that they are unable to trans phosphorylate each other (<xref rid="B7" ref-type="bibr">7</xref>). Therefore, larger oligomeric forms must exist so that the trans autophosphorylation event can take place.</p><p>NF-ÎºBâdependent gene expression is essential for stimulating the pro-inflammatory and immune responses to defend viral infections, and viruses such as vaccinia virus have, accordingly, evolved strategies to escape from the NF-ÎºBâdependent anti-viral immune response by inhibiting the activation of IKK (<xref rid="B16" ref-type="bibr">16</xref>). VACV encodes a 17-kDa protein, B14, that interacts directly with IKKÎ² to inhibit its activation, consequently blocking NF-ÎºB activation (<xref rid="B17" ref-type="bibr">17</xref>). The viral protein blocks phosphorylation of the activation segment of IKKÎ² to impede its activation but does not inhibit its kinase activity, as it has been shown to be incapable of inhibiting a constitutively active mutant form of IKKÎ² (S177E/S181E) (<xref rid="B18" ref-type="bibr">18</xref>). Interestingly, binding of B14 does not interfere with the assembly of the IKK holocomplex (<xref rid="B19" ref-type="bibr">19</xref>). In this study, we set out to elucidate the mechanism of VACV B14-mediated binding and inhibition of IKKÎ² activation. Study of this interaction has enlightened us regarding the mechanism of IKKÎ² activation from the perspective of a viral inhibitor. Dysregulation of the IKK/NF-ÎºB pathway is associated with numerous diseases, such as diabetes, cancer, and inflammatory and autoimmune diseases (<xref rid="B20" ref-type="bibr">20</xref>). Therefore, our study has provided critical structural and mechanistic information for the future design of new therapeutic agents to specifically target IKKÎ² activation for the treatment of these devastating human diseases.</p></sec><sec sec-type="results"><title>Results</title><sec><title>B14 inhibits IKKÎ² activation but not its kinase activity</title><p>Previous studies have shown that B14 inhibits IKKÎ² phosphorylation on Ser-177 and Ser-181 of its activation segment (<xref rid="B18" ref-type="bibr">18</xref>). In this study, we used the HEK293T cell overexpression system to examine human IKKÎ² autoactivation by assessing its phosphorylation on IÎºBÎ±. To elucidate the role of B14-mediated inhibition of IKKÎ² activation, we co-transfected HEK293T cells with both FLAG-IKKÎ² and HA-B14. IKKÎ² protein was then immunoprecipitated with anti-FLAG antibody, and its kinase activity was assessed in kinase assay with [Î³-<sup>32</sup>P]ATP. The purified recombinant human IÎºBÎ± protein was used as a substrate of IKKÎ². Consistent with other studies (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>), the viral protein B14 significantly inhibits IKKÎ² autoactivation in a dose-dependent manner (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>). Because varying amounts of B14 construct were co-transfected with the same amount of WT IKKÎ² construct, the inhibitory effect of B14 on IKKÎ² autoactivation can be manifested by its loss of activity on IÎºBÎ± phosphorylation. To rule out the possibility that B14 also inhibits the activated IKKÎ² with dual phosphorylation on Ser-177 and Ser-181 in the phosphorylation of IÎºBÎ±, we conducted an <italic>in vitro</italic> kinase assay with the purified recombinant IKKÎ²-SSEE (constitutively active S177E/S181E mutant). B14 did not show any distinguishable inhibitory effect on IKKÎ² kinase activity (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>), confirming that it does not inhibit the active IKKÎ².</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p><bold>The VACV protein B14 inhibits IKKÎ² activation but cannot impede its IÎºBÎ± kinase activity.</bold>
<italic>A</italic>, to elucidate the role of B14-mediated inhibition of IKKÎ² activation, we analyzed the kinase activity of autoactivated IKKÎ² in HEK293T cells co-transfected with full-length human IKKÎ² and varying amounts of B14 construct. The empty vector pcDNA3 was used to adjust the total DNA of 55 Î¼g used per transfection. <italic>IP</italic>, immunoprecipitation; <italic>WB</italic>, Western blot. <italic>B</italic>, to rule out the possibility that B14 also inhibits the activated IKKÎ² with dual phosphorylation on Ser-177 and Ser-181 in the phosphorylation of IÎºBÎ±, <italic>in vitro</italic> kinase assays with the constitutively active IKKÎ²-S177E/S181E (<italic>IKK</italic>Î²-<italic>SE</italic>) and B14 proteins were conducted. Maltose binding protein (<italic>MBP</italic>) was used as a negative control. Each experiment was repeated three times.</p></caption><graphic xlink:href="zbc0271889250001"/></fig></sec><sec><title>B14 binds both the KD and SDD of IKKÎ²</title><p>In the structure of IKKÎ², the KD, ULD, and SDD interact with each other to form an integral trimodular structural unit; however, the NBD has been shown to be an independently folded domain connected with a flexible linker to the rest of the protein (<xref rid="B21" ref-type="bibr">21</xref>). To map the B14 binding region on IKKÎ², we used a GSH S-transferase fusion B14 protein (GST-B14) to pull down the purified human IKKÎ² proteins (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>A</italic>). B14 binds to both full-length IKKÎ² and a construct without the NBD (4â675), indicating that the NBD is not required for B14âIKKÎ² interaction. In addition, B14 binds to both the constitutively active IKKÎ²-SSEE and inactive IKKÎ²-D145N, showing that its activation state does not affect B14 association. Furthermore, Ser-to-Glu or Ser-to-Ala substitutions on Ser-177 and Ser-181 of the activation segment do not influence B14 binding, suggesting that the binding may not engage the kinase activation segment.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p><bold>Map of the B14 interaction domains on human IKKÎ²</bold>. <italic>A</italic>, pulldown of IKKÎ² by GST-B14. GST protein alone was used as a negative control. <italic>IKK</italic>Î²<italic>-SE1</italic>, IKKÎ² (1â756) S177E/S181E; <italic>IKK</italic>Î²<italic>-SE2</italic>, IKKÎ² (1â678) S177E/S181E; <italic>IKK</italic>Î²<italic>-DN</italic>, IKKÎ² (1â756) D145N; <italic>IKK</italic>Î²<italic>-SA</italic>, IKKÎ² (1â756) S177A/S181A. <italic>B</italic> and <italic>C</italic>, pulldown of B14 by GST-IKKÎ² truncation mutant proteins. <italic>D</italic>, domain boundaries of the IKKÎ² constructs are shown on the <italic>right</italic>, and the binding property between each IKKÎ² construct and B14 is summarized on the <italic>left</italic>. Each experiment was repeated three times. <italic>M</italic> stands for protein molecular weight standard marker.</p></caption><graphic xlink:href="zbc0271889250002"/></fig><p>To determine the B14-interacting domains on IKKÎ², we expressed the GST fusion constructs of the KD (residues 1â307), KD-ULD (residues 1â384), ULD (residues 309â400), and ULD-SDD (residues 307â678) of human IKKÎ² in <italic>Escherichia coli</italic> (<xref ref-type="fig" rid="F2">Fig. 2</xref>, <italic>B</italic> and <italic>D</italic>). The recombinant GST-SDD constructs were not soluble, indicating that, when expressed alone separately, the SDD domain cannot be folded properly. We used the GST-IKKÎ² fusion proteins to pull down untagged B14 protein. All constructs pulled down B14, except GST-ULD, which clearly demonstrates that the ULD is not required for B14 binding to IKKÎ². GST alone did not bind B14, indicating that the binding between B14 and other IKKÎ² constructs is specific (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>B</italic>). The NBD of IKKÎ² does not contribute to IKKÎ² binding to B14 because the GST-NBD (residues 675â756) IKKÎ² construct did not pull down B14 (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>C</italic>). Based on the results, we can conclude that B14 interacts with IKKÎ² on the junction between KD and SDD domains.</p></sec><sec><title>The M2 and M4 regions of IKKÎ² are required for its interaction with B14</title><p>Because the crystal structures of both the VACV B14 and IKKÎ² proteins are available, we conducted computational molecular docking to reconstruct the B14âIKKÎ² interaction with FRODOCK (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). In parallel, we also used CLUSPRO (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>) to search for the binding interface, where the surface of the KD and SDD junction of IKKÎ² was chosen as a space restraint. We have included both the <italic>Xenopus</italic> IKKÎ² structure (PDB code <ext-link ext-link-type="pdb" xlink:href="3QA8">3QA8</ext-link>) in a closed conformation and a human IKKÎ² structure (PDB code <ext-link ext-link-type="pdb" xlink:href="4E3C">4E3C</ext-link>) in an open conformation for the modeling. We identified the same potential binding surface composed of both KD and SDD of both orthologous IKKÎ² structures. Five surface regions of IKKÎ², encompassing residues ranging from 179â197 (M1), 235â260 (M2), 408â416 (M4), 421â426 (M5), and 577â583 (M6) are contacting B14 in the docking models (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>A</italic>). To verify the docking models, we have substituted all residues of the M1 and M2 segments with Gly or Ser, mutated three key interacting residues (F182K, V183K, and L186K) of M3 on the GST-KD-ULD construct, and changed all residues on the M4, M5, and M6 segments to Gly or Ser on the GST-ULD-SDD construct. The GST fusion human IKKÎ² mutant constructs were then used to pull down the untagged B14 protein. We found that the M2 and M4 mutants have an almost 60% lower binding affinity compared with the WT constructs. The M6 mutant has a light decrease in its interaction with B14, whereas the M1, M3, and M5 mutants have no significant changes in B14 binding (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>B</italic> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S1</ext-link>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><bold>The M2 and M4 segments of IKKÎ² are required for B14 binding.</bold>
<italic>A</italic>, molecular docking models of IKKÎ²âB14 interaction. The KD, ULD, and SDD of human IKKÎ² (PDB ID <ext-link ext-link-type="pdb" xlink:href="4E3C">4E3C</ext-link>) are colored <italic>yellow</italic>, <italic>pink</italic>, and <italic>slate</italic>, respectively. The potential B14-interacting segments present on IKKÎ² protein are shown as <italic>M1</italic>, <italic>M2</italic>, and <italic>M4-M6</italic> and colored <italic>cyan</italic>, <italic>blue</italic>, <italic>magenta</italic>, <italic>green</italic>, and <italic>orange</italic>, respectively. Three residues, Phe-182, Val-183, and Leu-186 on the M3 segment, are shown in <italic>stick representation</italic> and colored <italic>cyan. B</italic>, pulldown of B14 by GST-IKKÎ² mutants. GST protein alone was used as a negative control. GST-IKKÎ²-KD-ULD contains residues 1â384 of human IKKÎ², and GST-IKKÎ²-ULD-SDD harbors residues 307â678 of human IKKÎ², both of which are used as the WT positive controls (<italic>WT1</italic> and <italic>WT2</italic>). In addition, the M1 mutant has residues 179â197substituted with GGGGSGGS, M2 has residues 235â260 replaced with GGGGSGGS, M3 contains F182K/V183K/L186K mutations, M4 has residues 408â416 replaced with GGGGS, M5 has residues 421â426 substituted with GGGGS, and M6 has residues 577â583 replaced with GGGGS. <italic>C</italic>, the B14 structure is represented as a <italic>ribbon diagram</italic> and is colored <italic>cyan</italic>, with the potential IKKÎ² interacting residues shown as <italic>stick representation</italic> and colored <italic>magenta. D</italic>, pulldown of human IKKÎ² (1â675, S177E/S181E) by GST-B14 mutants. All experiments were repeated three times and yielded similar results. <italic>M</italic> stands for protein molecular weight standard marker.</p></caption><graphic xlink:href="zbc0271889250003"/></fig><p>Based on the molecular docking modeling, the residues Thr-31, Tyr-35, Leu-126, and Phe-130 present on the surface of B14 can potentially contact IKKÎ² (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>C</italic>). Phe-130 of B14 has been demonstrated previously to be required for IKKÎ² binding and inhibition (<xref rid="B19" ref-type="bibr">19</xref>) and, in turn, it validates our modeling results. To test which of the residues contribute to B14 interaction with IKKÎ², we created single-substitution mutant constructs of GST-B14 to pull down the full-length human IKKÎ² protein (<xref ref-type="fig" rid="F3">Fig. 3</xref><italic>D</italic> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S1<italic>C</italic></ext-link>). Both the mutants T31K and Y35E demonstrated a significant decrease in binding affinity as the WT B14 to IKKÎ²; L126E had a slight loss of binding, whereas F130K had negligible binding to IKKÎ². This is consistent with a previous study showing that the B14 F130K mutant protein not only lost its binding to IKKÎ² but was also unable to inhibit NF-ÎºB signaling (<xref rid="B19" ref-type="bibr">19</xref>). We postulate that Phe-130 and Leu-126 of B14 are likely to create a small hydrophobic surface patch to bind the KD and SDD junction surface of IKKÎ² in forming the inhibitory complex.</p></sec><sec><title>Binding of B14 to IKKÎ² does not block the kinase activation segment</title><p>We used the identified interface to perform a local search with a molecular docking program, ROSETTA (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). We also included both the <italic>Xenopus</italic> IKKÎ² structure (PDB code <ext-link ext-link-type="pdb" xlink:href="3QA8">3QA8</ext-link>) in a closed conformation and a human IKKÎ² structure (PDB code <ext-link ext-link-type="pdb" xlink:href="4E3C">4E3C</ext-link>) in an open conformation for the modeling to indicate the evolutionarily conserved B14 binding. In these refined binding models, the small hydrophobic patch centered on Phe-130 of B14 interacts with both the M2 and M4 segments of IKKÎ², which has no contact with the activation segment of the kinase domain (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <italic>AâD</italic>). To verify this predicted binding interface, we created six full-length human IKKÎ² mutants with the substitutions L259K, Y261A, V410K, L259K/Y261A, and L259K/Y261A/V410K, and the M2M4 mutant. These mutants were expressed in human kidney embryonic 293F (HEK293F) cells with an engineered N-terminal FLAG tag. The mutant recombinant proteins were used to pull down purified GST fusion B14 protein expressed in <italic>E. coli</italic>. The IKKÎ² L259K/Y261A/V410K mutant was not expressed in HEK293F cells, indicating that substituting all three residues disturbs its proper folding and stability. The L259K and L259K/Y261A mutations severely weakened IKKÎ² binding to B14, whereas V410K or Y261A alone had a minor effect on their interaction (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>E</italic>). Tyr-261 is not conserved in <italic>Xenopus</italic> IKKÎ² (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>C</italic>), indicating that Tyr-261 is not critical. The M2M4 mutant has a similar binding pattern to B14 as L259K/Y261A. This shows that the three chosen residues in the M2M4 regions account for most of the binding affinity for B14. In this confirmed binding model of both the closed and open IKKÎ² structures, the activation segment of the kinase domain is exposed for substrate binding, which explains why B14 does not directly inhibit IKKÎ² kinase activity.</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4.</label><caption><p><bold>B14-IKKÎ² binding interface.</bold>
<italic>A</italic> and <italic>B</italic>, models of B14/IKKÎ² complex structures. Closed <italic>Xenopus</italic> IKKÎ² (xIKKÎ², PDB code <ext-link ext-link-type="pdb" xlink:href="3QA8">3QA8</ext-link>, <italic>A</italic>) and open human IKKÎ² (hIKKÎ², PDB code <ext-link ext-link-type="pdb" xlink:href="4E3C">4E3C</ext-link>, <italic>B</italic>) structures are shown as <italic>ribbons</italic> and colored <italic>green</italic>. VACV B14 is shown as a ribbon and colored <italic>cyan</italic>. M2, M4, and the activation segment of IKKÎ² (<italic>AS</italic>) are colored <italic>blue</italic>, <italic>magenta</italic>, and <italic>red</italic>, respectively. <italic>C</italic> and <italic>D</italic>, B14-IKKÎ² binding interface for xIKKÎ² and hIKKÎ², respectively. The key interacting residues are shown as <italic>sticks. E</italic>, GST-B14 was pulled down by human WT and mutant IKKÎ². The empty vector was expressed as a control. <italic>LY</italic> refers to the L259K and Y261A IKKÎ² double mutant. The M2M4 IKKÎ² mutant contains both the M2 and M4 substitutions described in <xref ref-type="fig" rid="F3">Fig. 3</xref>. <italic>WB</italic>, Western blot. The experiment was repeated three times with consistent results.</p></caption><graphic xlink:href="zbc0271889250004"/></fig></sec><sec><title>A model for B14-mediated inhibition of IKKÎ² activation</title><p>Our previous measurement of the recombinant full-length human NEMO and IKKÎ² proteins by size exclusion chromatography with multiangle light scattering has shown their dimeric status in solution. The measured molecular mass of the reconstituted IKK complex is around 2000 kDa, which corresponds to â¼12â16 NEMO and IKKÎ² molecules in each complex assembly (<xref rid="B28" ref-type="bibr">28</xref>). Based on this study, we postulate that, instead of one NEMO binding to one IKKÎ² molecule to form a heterodimer, NEMO uses each of its two kinase binging domains to interact with an NBD in two separate IKKÎ² molecules. In this mode of alternating binding, the NEMO protein cross-links IKKÎ² to form a high-order oligomer in which trans autophosphorylation and activation can occur (<xref ref-type="fig" rid="F5">Fig. 5</xref> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S2<italic>B</italic></ext-link>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5.</label><caption><p><bold>A model for B14-mediated inhibition of IKKÎ² activation.</bold> The KBD of NEMO interacts with the NBD of IKKÎ², which cross-links IKKÎ² to a large oligomer. Upon activation by upstream signaling events or by high IKK concentration, the activation segments of the neighboring KDs can contact each other for trans autophosphorylation. Binding of B14 to the junction of KD and SDD of IKKÎ² causes a steric hindrance that impedes the optimal contact between KDs in the IKK complex, which, in turn, blocks the insertion of the activation segment of one KD to the active site of another for trans autophosphorylation and activation.</p></caption><graphic xlink:href="zbc0271889250005"/></fig><p>The crystal structures of the IKKÎ² dimer have distinct closed and open conformations (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). There is a certain degree of flexibility in the SDD domain so that the KD and the proximal region of SDD can swing toward or away to adopt either a closed or an open dimer conformation (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S2</ext-link>). In the <italic>Xenopus</italic> IKKÎ² structure, although it is an S177E/S181E constitutively active mutant, the presence of a specific kinase inhibitor renders it in an inactive kinase form, and IKKÎ² adopts a closed dimer conformation (<xref rid="B7" ref-type="bibr">7</xref>). Surprisingly, the active human IKKÎ² is in a unique open dimer conformation (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). The IKKÎ² structure may vary between multiple transitional conformations in solution, as proposed previously, or probably the closed conformation represents the inactive state, whereas the open conformation indicates the active state.</p><p>We hypothesize that the IKKÎ² undergoes at least two transitional stages during its activation, a preactivation complex and a postactivation (activated) complex. In the preactivation complex, the activation segments of the neighboring KDs can contact each other for trans autophosphorylation (<xref ref-type="fig" rid="F5">Fig. 5</xref> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S2</ext-link>). It is possible that, in the preactivation IKK complex, NEMO âprimesâ IKKÎ² for activation by upstream signaling events, such as polyubiquitin chain binding or phosphorylation by an upstream kinase (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). The dependence of signaling for the IKKÎ² activation can be overcome by a high IKK concentration, as the NEMOâIKKÎ² complex can be activated when overexpressed (<xref rid="B11" ref-type="bibr">11</xref>). Although, in the postactivation complex, large conformational changes occur to allow the kinase domains to swing away from each other, making room for substrate binding and catalysis. Binding of B14 to the junction of the KD and SDD of IKKÎ² causes a steric hindrance that impedes optimal contact between KDs in the IKK complex. This structural rearrangement, in turn, blocks insertion of the activation segment of one KD to the active site of another for trans autophosphorylation (<xref ref-type="fig" rid="F5">Fig. 5</xref> and <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S3</ext-link>). B14 binds to both the constitutively active and inactive IKKÎ² proteins with comparable affinity (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>A</italic>). However, its binding to the preactivation complex stops the KD interactions, precluding trans autophosphorylation and activation. B14 can associate with the postactivation complex with little effect on the activity of the kinase (<xref ref-type="fig" rid="F1">Figs. 1</xref><italic>B</italic> and <italic><xref ref-type="fig" rid="F2">2</xref>A</italic>) because the binding site of B14 on IKKÎ² has no overlap with the kinase substrate binding site and the active site (<xref ref-type="fig" rid="F4">Fig. 4</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Mechanism of B14-mediated IKKÎ² inhibition</title><p>Our biochemical and computational characterization of B14âIKKÎ² interaction has identified a B14 binding interface consisting of both the KD and SDD of IKKÎ². Although B14 inhibited IÎºBÎ± phosphorylation in both our autoactivation assay (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>) and the previously reported <italic>in vivo</italic> experiment in HEK293T cells (<xref rid="B18" ref-type="bibr">18</xref>), our <italic>in vitro</italic> kinase inhibition assay clearly shows that B14 does not directly inhibit IÎºBÎ± phosphorylation by the activated IKKÎ² (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>B</italic>). Because B14 binding attenuates IKKÎ² dual phosphorylation on Ser-177 and Ser-181 (<xref rid="B18" ref-type="bibr">18</xref>), which is required for IKKÎ² to confer kinase activity, we conclude that B14 specifically targets IKKÎ² trans autophosphorylation to impede its <italic>in vivo</italic> kinase activity. We propose that the B14 interaction creates steric hindrance to prevent the KDs of IKKÎ² moving in proximity (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S3</ext-link>), which is a prelude for trans autophosphorylation and kinase activation. The B14 binding leaves some space between the activation segment and the B14 protein molecule. In principle, the activation segment of one IKKÎ² molecule can still have the chance to contact the active site of another for trans phosphorylation. The KD of IKKÎ² forms an ensemble with the SDD and ULD, and that restricts the access of the active site of one KD with the activation segment of another. In addition, the dimeric structure of IKKÎ² further limits the proximity of the active segment and active site of KDs, thereby restricting chances of trans autophosphorylation. It also indicates that, in the presence of the scaffold protein NEMO, the activation of IKKÎ² requires a well-defined structural architecture of the kinase complex that can allow optimal contact between the kinase domains.</p></sec><sec><title>Impact of IKKÎ² oligomerization on its activation and B14 inhibition</title><p>Although IKKÎ² stays as a dimer in solution, different types of oligomers have been observed in the crystal structures of both human and <italic>Xenopus</italic> IKKÎ²s (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). In the crystal structures of both <italic>Xenopus</italic> and human IKKÎ²s lacking the NBD, two IKKÎ² dimers interact on the KD-proximal side of the structure to form a crystal packing tetramer. Because the activation segment of protein kinases has the potential to undergo conformational changes (<xref rid="B31" ref-type="bibr">31</xref>), the activation segment of one dimer is able to contact the active site of the other dimer for trans autophosphorylation in the observed crystal packing oligomers (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). In a crystal structure of human IKKÎ² without the NBD, the two KDs from two different IKKÎ² dimers form a V-shaped interface to permit trans autophosphorylation (<xref rid="B29" ref-type="bibr">29</xref>). Based on the modeling studies, with B14 binding to either IKKÎ² oligomers observed in the three different crystal structures, it blocks the contact of the KDs in all interfaces (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S3</ext-link>). Under <italic>in vivo</italic> condition, IKKÎ² needs to be activated in the NEMOâIKKÎ² complex. However, in the absence of an IKK holocomplex structure, it cannot be concluded that the observed KD interfaces in the crystal structures are relevant for IKKÎ² trans autophosphorylation <italic>in vivo</italic>. Our computational modeling of the B14âIKKÎ² interaction in all three crystal packing complexes indicates that the mode of B14 binding to IKKÎ² is an effective way to block the trans autophosphorylation between neighboring IKKÎ² dimers (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S3</ext-link>). This is consistent with the experimental observation that co-expression of B14 and IKKÎ² inhibits the IKKÎ² trans autoactivation induced by overexpression (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>A</italic>).</p></sec><sec><title>Differential binding and inhibition of IKKÎ± and IKKÎ² by B14</title><p>B14 has been shown to have no observable binding to IKKÎ± (<xref rid="B18" ref-type="bibr">18</xref>), which indicates that it specifically targets IKKÎ² to stop the anti-inflammatory canonical NF-ÎºB signaling. Based on the sequence alignment of both human IKKÎ± and IKKÎ² (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S4<italic>A</italic></ext-link>), the two important residues of IKKÎ² that are required for binding to B14, Tyr-259 and Val-410, are conserved in IKKÎ±. However, structural analysis of IKKÎ± has revealed a huge structural variation on the corresponding B14 binding interface in IKKÎ± (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Fig. S4<italic>B</italic></ext-link>), which explains the lack of B14 binding to IKKÎ±. However, the low resolution (4.5 â«) of the IKKÎ± structure limits the reliability of this structural comparison to draw any conclusions (<xref rid="B32" ref-type="bibr">32</xref>). More structural <italic>in vitro</italic> and <italic>in vivo</italic> binding studies and kinase assays on B14 and IKKÎ± interactions are needed to address this question in the future.</p></sec><sec><title>Possibility of B14 inhibition of IKKÎ² activation by TAK1 phosphorylation</title><p>Some other studies have shown that the kinase TAK1 can activate IKKÎ² by directly phosphorylating the activation segment of IKKÎ² (<xref rid="B30" ref-type="bibr">30</xref>). It is not known whether the KD of TAK1 also forms a large multidomain integral structure with the rest of the protein, although it has been demonstrated that the KD alone of TAK1 is crystallizable and can be activated by binding to TAB1 (TAK1-binding protein 1), which is capable of forming an ensemble structure like IKKÎ², but TAB1 is not necessary for TAK1 kinase activity (<xref rid="B33" ref-type="bibr">33</xref>). A free KD of TAK1, therefore, will have more rotation mobility and accessibility to contact the activation segment of IKKÎ² for phosphorylation than being held in a larger complex with other domains or proteins. In that case, it is unlikely that the B14 binding will inhibit TAK1 phosphorylation of IKKÎ². This implies that phosphorylation by an upstream kinase is not the decisive step for IKKÎ² activation and that trans autophosphorylation is the main mechanism. Therefore, phosphorylation by TAK1 is merely a priming event that may trigger or augment IKKÎ² activation. It remains to be tested experimentally whether the presence of B14 indeed has any effect on TAK1 phosphorylation of IKKÎ².</p></sec><sec><title>Future structural and in vivo studies to investigate the mechanism of B14-mediated inhibition of IKKÎ² activation</title><p>In this study, we mainly focused on mapping the interaction interface between IKKÎ² and B14. For a deeper understanding of B14-mediated inhibition of IKKÎ² activation, structural characterization of both the NEMOâIKKÎ² and B14âNEMOâIKKÎ² protein complexes needs to be carried out by X-ray crystallography or cryo-EM. Structural comparisons between both complex structures will provide more mechanistic and molecular insights into IKKÎ² activation and B14 inhibition. Furthermore, conducting <italic>in vivo</italic> studies to look for NF-ÎºB signaling outcomes is necessary to improve our understanding of B14-mediated IKKÎ² inhibition.</p></sec></sec><sec sec-type="methods"><title>Experimental procedures</title><sec><title>Protein expression and purification</title><p>Various constructs of human IKKÎ² WT and the phosphomimic S177E/S181E mutants were designed with an N-terminal polyhistidine tag and a tobacco etch virus protease cutting site engineered between the tag and the protein. Recombinant IKKÎ² baculoviruses were made in DH10BAC cells, amplified, and used to infect Hi5 insect cells in serum-free medium (Invitrogen and Pharmingen). The cells were cultured in suspension and harvested 48 h post-infection. The recombinant proteins were purified by nickel affinity chromatography, anion exchange, and gel filtration chromatography. The polyhistidine tag was cleaved by the tobacco etch virus protease during protein purification.</p><p>All human IÎºBÎ± and VACV B14 proteins were expressed in <italic>E. coli</italic> using pET28a and pGEX4T3 vectors and purified by their respective affinity tags. GST-KD, GST-KD-ULD, GST-ULD, and GST-ULD-SDD of human IKKÎ² were also expressed in <italic>E. coli</italic> using pGEX4T3 vectors. The tagged proteins were first purified with GSH or nickel-nitrilotriacetic acid beads, and their expression levels were assessed by SDS-PAGE.</p></sec><sec><title>Transfection, immunoprecipitation, and kinase assay</title><p>The HA-B14 construct, Flag-IKKÎ², and its mutant constructs were generated in the pcDNA3 vector using conventional PCR. HEK293T or HEK293F cells were transfected with all constructs using Lipofectamine 2000 (Invitrogen). After 24 h, cell extracts were immunoprecipitated with anti-FLAG antibodies bound to agarose beads (M2, Sigma). IKKÎ² kinase assays were essentially done as described previously (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B34" ref-type="bibr">34</xref>). The immunoprecipitants were incubated with 2 Î¼<sc>m</sc> full-length IÎºBÎ± in 20 m<sc>m</sc> HEPES (pH 7.5), 10 m<sc>m</sc> MgCl<sub>2</sub>, 20 m<sc>m</sc> Î²-glycerophosphate, 10 m<sc>m</sc>
<italic>p</italic>-nitrophenyl phosphate, 50 m<sc>m</sc> Na<sub>3</sub>VO<sub>4</sub>, 1 m<sc>m</sc> DTT, 20 m<sc>m</sc> ATP, and 1â10 mCi)[Î³-<sup>32</sup>P]ATP at 30 Â°C for 30 min and subjected to SDS-PAGE and autoradiography. Immunoblotting was performed using anti-FLAG (Sigma) or anti-HA (Sigma) antibodies (Upstate, 05-535). For the <italic>in vitro</italic> IKKÎ² kinase assay, purified recombinant IKKÎ²-S177ES/182E mutant protein was mixed with varying amounts of recombinant B14 or maltose binding protein as described above.</p></sec><sec><title>Pulldown assays</title><p>For GST pulldown, the tagged proteins were purified with GSH or nickel-nitrilotriacetic acid beads, followed by purification with gel filtration using a SuperdexG200 10/300 column (GE Healthcare). The expression levels were assessed by SDS-PAGE. Beads containing estimated equivalent quantities of the GST-tagged proteins were mixed with the purified versions of the interacting partners. The mixtures were incubated at 4 Â°C for 2 h with continuous rotation on a rocking platform. After centrifugation, the supernatants were removed. The beads were then washed three times with buffer (50 m<sc>m</sc> Tris-HCl (pH 8.0), 100 m<sc>m</sc> NaCl, 2 m<sc>m</sc> Î²-mercaptoethanol, and 5 m<sc>m</sc> DTT) and eluted with 25 m<sc>m</sc> reduced GSH, and the elutions were subjected to SDS-PAGE analysis. All GST pulldown experiments were repeated at least three times for consistency.</p><p>For FLAG pulldown, FLAG-tagged human IKKÎ² and mutant proteins expressed in HEK293F cells were lysed in buffer containing 50 m<sc>m</sc> Tris-HCl (pH 8.0), 100 m<sc>m</sc> NaCl, 2 m<sc>m</sc> Î²-mercaptoethanol, 5 m<sc>m</sc> DTT, 2% NP40, and a protease inhibitor mixture. The protein was then mixed with anti-FLAG antibody (Sigma), purified GST-B14 protein, and protein A/Gâagarose (Thermo Scientific). The resultant protein complex was eluted by 200 Î¼g/ml FLAG peptide (Sigma) and subsequently used for Western blotting with anti-FLAG or anti-GST antibodies. The image was captured by G:Box imaging systems. All experiments were repeated at least three times.</p></sec><sec><title>Protein molecular docking</title><p>Two IKKÎ² structures (PDB codes <ext-link ext-link-type="pdb" xlink:href="3QA8">3QA8</ext-link> (<xref rid="B7" ref-type="bibr">7</xref>) and <ext-link ext-link-type="pdb" xlink:href="4E3C">4E3C</ext-link> (<xref rid="B23" ref-type="bibr">23</xref>)) were selected as the receptors, and the B14 structure (PDB code <ext-link ext-link-type="pdb" xlink:href="2VVY">2VVY</ext-link> (<xref rid="B17" ref-type="bibr">17</xref>)) was selected as the ligand. First, the FRODOCK interactive proteinâprotein docking (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>) (<ext-link ext-link-type="uri" xlink:href="http://frodock.chaconlab.org/">http://frodock.chaconlab.org/</ext-link>)<xref ref-type="fn" rid="FN2"><sup>3</sup></xref> online server was used for a global search to provide the potential binding position information. Because GST pulldown experiments show that the M2 and M4 segments of IKKÎ² are involved in binging to B14, and Phe-130 of B14 is required for IKKÎ² interaction, we next used the Cluspro 2.0 proteinâprotein docking (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>) online server (<ext-link ext-link-type="uri" xlink:href="https://cluspro.bu.edu/">https://cluspro.bu.edu/</ext-link>)<sup>3</sup> to obtain more accurate complex models with these defined interfaces as restraints. The top ten models were analyzed, and the best-fitting one was chosen as an initial complex model for subsequent optimization with the Rosetta docking 2 (<ext-link ext-link-type="uri" xlink:href="http://rosie.rosettacommons.org/">http://rosie.rosettacommons.org/</ext-link>)<sup>3</sup> online server (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). Local docking was chosen as the docking protocol.</p></sec></sec><sec><title>Author contributions</title><p>Q. T., S. C., and G. X. conceptualization; Q. T. and G. X. resources; Q. T., S. C., and G. X. data curation; Q. T. software; Q. T., S. C., and G. X. formal analysis; Q. T. and S. C. validation; Q. T. and G. X. investigation; Q. T. and S. C. visualization; Q. T. and S. C. methodology; Q. T. and G. X. writing-original draft; Q. T., S. C., and G. X. writing-review and editing; G. X. supervision; G. X. funding acquisition; G. X. project administration.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supporting Information</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_293_26_10344__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_RA118.002817_J136546_2_supp_132058_p86149.pdf"/>
</supplementary-material>
</sec>
</body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>This work was supported by National Institutes of Health Grant 5R01AI118769 and new faculty startup funds from North Carolina State University (to G. X.). <named-content content-type="COI-statement">The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health</named-content>.</p>
      </fn>
      <fn fn-type="supplementary-material">
        <p>This article contains <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/RA118.002817/DC1">Figs. S1âS4</ext-link>.</p>
      </fn>
      <fn fn-type="other" id="FN2">
        <label>3</label>
        <p>Please note that the JBC is not responsible for the long-term archiving and maintenance of this site or any other third partyâhosted site.</p>
      </fn>
    </fn-group>
    <fn-group content-type="abbreviations">
      <fn id="FN1">
        <label>2</label>
        <p>The abbreviations used are:
<def-list><def-item><term id="G1">IKK</term><def><p>inhibitor of ÎºB kinase</p></def></def-item><def-item><term id="G2">NEMO</term><def><p>NF-ÎºB essential modifier</p></def></def-item><def-item><term id="G3">KD</term><def><p>kinase domain</p></def></def-item><def-item><term id="G4">ULD</term><def><p>ubiquitin-like domain</p></def></def-item><def-item><term id="G5">SDD</term><def><p>scaffold and dimerization domain</p></def></def-item><def-item><term id="G6">NBD</term><def><p>NEMO-binding domain</p></def></def-item><def-item><term id="G7">VACV</term><def><p>vaccinia virus</p></def></def-item><def-item><term id="G8">HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term id="G9">GST</term><def><p>glutathione <italic>S</italic>-transferase</p></def></def-item><def-item><term id="G10">HEK</term><def><p>human embryonic kidney.</p></def></def-item></def-list></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank Dr. Hao Wu for allowing G. X. to carry out the kinase assays in her laboratory at Boston Children's Hospital. We thank Dr. Dave Presutti for allowing us to use the G:Box BioImaging Systems for Western blotting.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vallabhapurapu</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>) <article-title>Regulation and function of NF-ÎºB transcription factors in the immune system</article-title>. <source>Annu. Rev. Immunol</source>. <volume>27</volume>, <fpage>693</fpage>â<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132641</pub-id>
<?supplied-pmid 19302050?><pub-id pub-id-type="pmid">19302050</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hayden</surname><given-names>M. S.</given-names></name>, and <name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name></person-group> (<year>2012</year>) <article-title>NF-ÎºB, the first quarter-century: remarkable progress and outstanding questions</article-title>. <source>Genes Dev</source>. <volume>26</volume>, <fpage>203</fpage>â<lpage>234</lpage>
<pub-id pub-id-type="doi">10.1101/gad.183434.111</pub-id>
<?supplied-pmid 22302935?><pub-id pub-id-type="pmid">22302935</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scheidereit</surname><given-names>C.</given-names></name></person-group> (<year>2006</year>) <article-title>IÎºB kinase complexes: gateways to NF-ÎºB activation and transcription</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>6685</fpage>â<lpage>6705</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1209934</pub-id>
<?supplied-pmid 17072322?><pub-id pub-id-type="pmid">17072322</pub-id></mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Napetschnig</surname><given-names>J.</given-names></name>, and <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>) <article-title>Molecular basis of NF-ÎºB signaling</article-title>. <source>Annu. Rev. Biophys</source>. <volume>42</volume>, <fpage>443</fpage>â<lpage>468</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-biophys-083012-130338</pub-id>
<?supplied-pmid 23495970?><pub-id pub-id-type="pmid">23495970</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hinz</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Arslan</surname><given-names>S. Ã.</given-names></name>, and <name name-style="western"><surname>Scheidereit</surname><given-names>C.</given-names></name></person-group> (<year>2012</year>) <article-title>It takes two to tango: IÎºBs, the multifunctional partners of NF-ÎºB</article-title>. <source>Immunol. Rev</source>. <volume>246</volume>, <fpage>59</fpage>â<lpage>76</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01102.x</pub-id>
<?supplied-pmid 22435547?><pub-id pub-id-type="pmid">22435547</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huxford</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>A.</given-names></name>, and <name name-style="western"><surname>Ghosh</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>) <article-title>Understanding the logic of IÎºB:NF-ÎºB regulation in structural terms</article-title>. <source>Curr. Top. Microbiol. Immunol</source>. <volume>349</volume>, <fpage>1</fpage>â<lpage>24</lpage>
<?supplied-pmid 20845107?><pub-id pub-id-type="pmid">20845107</pub-id></mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Lo</surname><given-names>Y. C.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Napolitano</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Dreano</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name></person-group> (<year>2011</year>) <article-title>Crystal structure of inhibitor of ÎºB kinase Î²</article-title>. <source>Nature</source>
<volume>472</volume>, <fpage>325</fpage>â<lpage>330</lpage>
<pub-id pub-id-type="doi">10.1038/nature09853</pub-id>
<?supplied-pmid 21423167?><pub-id pub-id-type="pmid">21423167</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zandi</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>, and <name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group> (<year>1998</year>) <article-title>Direct phosphorylation of IÎºB by IKKÎ± and IKKÎ²: discrimination between free and NF-ÎºB-bound substrate</article-title>. <source>Science</source>
<volume>281</volume>, <fpage>1360</fpage>â<lpage>1363</lpage>
<pub-id pub-id-type="doi">10.1126/science.281.5381.1360</pub-id>
<?supplied-pmid 9721103?><pub-id pub-id-type="pmid">9721103</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>E. D.</given-names></name>, <name name-style="western"><surname>Inohara</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>C. Y.</given-names></name>, <name name-style="western"><surname>NuÃ±ez</surname><given-names>G.</given-names></name>, and <name name-style="western"><surname>Guan</surname><given-names>K. L.</given-names></name></person-group> (<year>2003</year>) <article-title>Roles for homotypic interactions and transautophosphorylation in IÎºB kinase Î² IKKÎ²) activation [corrected]</article-title>. <source>J. Biol. Chem</source>. <volume>278</volume>, <fpage>38566</fpage>â<lpage>38570</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M304374200</pub-id>
<?supplied-pmid 12890679?><pub-id pub-id-type="pmid">12890679</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Lawrence</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Peggie</surname><given-names>M. W.</given-names></name>, and <name name-style="western"><surname>Cohen</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>) <article-title>An unexpected twist to the activation of IKKÎ²: TAK1 primes IKKÎ² for activation by autophosphorylation</article-title>. <source>Biochem. J</source>. <volume>461</volume>, <fpage>531</fpage>â<lpage>537</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20140444</pub-id>
<?supplied-pmid 24911653?><pub-id pub-id-type="pmid">24911653</pub-id></mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>B. S.</given-names></name>, and <name name-style="western"><surname>Zandi</surname><given-names>E.</given-names></name></person-group> (<year>2001</year>) <article-title>Complete reconstitution of human IÎºB kinase (IKK) complex in yeast: assessment of its stoichiometry and the role of IKKÎ³ on the complex activity in the absence of stimulation</article-title>. <source>J. Biol. Chem</source>. <volume>276</volume>, <fpage>36320</fpage>â<lpage>36326</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M104051200</pub-id>
<?supplied-pmid 11470787?><pub-id pub-id-type="pmid">11470787</pub-id></mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X. H.</given-names></name>, <name name-style="western"><surname>Fang</surname><given-names>X.</given-names></name>, and <name name-style="western"><surname>Gaynor</surname><given-names>R. B.</given-names></name></person-group> (<year>2001</year>) <article-title>Role of IKKÎ³/nemo in assembly of the IÎº B kinase complex</article-title>. <source>J. Biol. Chem</source>. <volume>276</volume>, <fpage>4494</fpage>â<lpage>4500</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M008353200</pub-id>
<?supplied-pmid 11080499?><pub-id pub-id-type="pmid">11080499</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z. J.</given-names></name></person-group> (<year>2012</year>) <article-title>Ubiquitination in signaling to and activation of IKK</article-title>. <source>Immunol. Rev</source>. <volume>246</volume>, <fpage>95</fpage>â<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01108.x</pub-id>
<?supplied-pmid 22435549?><pub-id pub-id-type="pmid">22435549</pub-id></mixed-citation>
      </ref>
      <ref id="B14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>Z. P.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Pineda</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Adhikari</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>W.</given-names></name>, and <name name-style="western"><surname>Chen</surname><given-names>Z. J.</given-names></name></person-group> (<year>2009</year>) <article-title>Direct activation of protein kinases by unanchored polyubiquitin chains</article-title>. <source>Nature</source>
<volume>461</volume>, <fpage>114</fpage>â<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1038/nature08247</pub-id>
<?supplied-pmid 19675569?><pub-id pub-id-type="pmid">19675569</pub-id></mixed-citation>
      </ref>
      <ref id="B15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rudolph</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Yeh</surname><given-names>W. C.</given-names></name>, <name name-style="western"><surname>Wakeham</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Rudolph</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Nallainathan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Potter</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Elia</surname><given-names>A. J.</given-names></name>, and <name name-style="western"><surname>Mak</surname><given-names>T. W.</given-names></name></person-group> (<year>2000</year>) <article-title>Severe liver degeneration and lack of NF-ÎºB activation in NEMO/IKKÎ³-deficient mice</article-title>. <source>Genes Dev</source>. <volume>14</volume>, <fpage>854</fpage>â<lpage>862</lpage>
<?supplied-pmid 10766741?><pub-id pub-id-type="pmid">10766741</pub-id></mixed-citation>
      </ref>
      <ref id="B16">
        <label>16.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hiscott</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Nguyen</surname><given-names>T. L.</given-names></name>, <name name-style="western"><surname>Arguello</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nakhaei</surname><given-names>P.</given-names></name>, and <name name-style="western"><surname>Paz</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>) <article-title>Manipulation of the nuclear factor-ÎºB pathway and the innate immune response by viruses</article-title>. <source>Oncogene</source>
<volume>25</volume>, <fpage>6844</fpage>â<lpage>6867</lpage>
<pub-id pub-id-type="doi">10.1038/sj.onc.1209941</pub-id>
<?supplied-pmid 17072332?><pub-id pub-id-type="pmid">17072332</pub-id></mixed-citation>
      </ref>
      <ref id="B17">
        <label>17.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>S. C.</given-names></name>, <name name-style="western"><surname>Bahar</surname><given-names>M. W.</given-names></name>, <name name-style="western"><surname>Cooray</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>Whalen</surname><given-names>D. M.</given-names></name>, <name name-style="western"><surname>Abrescia</surname><given-names>N. G.</given-names></name>, <name name-style="western"><surname>Alderton</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Owens</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>D. I.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>G. L.</given-names></name>, and <name name-style="western"><surname>Grimes</surname><given-names>J. M.</given-names></name></person-group> (<year>2008</year>) <article-title>Vaccinia virus proteins A52 and B14 Share a Bcl-2-like fold but have evolved to inhibit NF-ÎºB rather than apoptosis</article-title>. <source>PLoS Pathog</source>. <volume>4</volume>, <fpage>e1000128</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1000128</pub-id>
<?supplied-pmid 18704168?><pub-id pub-id-type="pmid">18704168</pub-id></mixed-citation>
      </ref>
      <ref id="B18">
        <label>18.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R. A.</given-names></name>, <name name-style="western"><surname>Ryzhakov</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Cooray</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Randow</surname><given-names>F.</given-names></name>, and <name name-style="western"><surname>Smith</surname><given-names>G. L.</given-names></name></person-group> (<year>2008</year>) <article-title>Inhibition of IÎºB kinase by vaccinia virus virulence factor B14</article-title>. <source>PLoS Pathog</source>. <volume>4</volume>, <fpage>e22</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.0040022</pub-id>
<?supplied-pmid 18266467?><pub-id pub-id-type="pmid">18266467</pub-id></mixed-citation>
      </ref>
      <ref id="B19">
        <label>19.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Benfield</surname><given-names>C. T.</given-names></name>, <name name-style="western"><surname>Mansur</surname><given-names>D. S.</given-names></name>, <name name-style="western"><surname>McCoy</surname><given-names>L. E.</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>B. J.</given-names></name>, <name name-style="western"><surname>Bahar</surname><given-names>M. W.</given-names></name>, <name name-style="western"><surname>Oldring</surname><given-names>A. P.</given-names></name>, <name name-style="western"><surname>Grimes</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Stuart</surname><given-names>D. I.</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>S. C.</given-names></name>, and <name name-style="western"><surname>Smith</surname><given-names>G. L.</given-names></name></person-group> (<year>2011</year>) <article-title>Mapping the IÎºB kinase beta (IKKÎ²)-binding interface of the B14 protein, a vaccinia virus inhibitor of IKKÎ²-mediated activation of nuclear factor ÎºB</article-title>. <source>J. Biol. Chem</source>. <volume>286</volume>, <fpage>20727</fpage>â<lpage>20735</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M111.231381</pub-id>
<?supplied-pmid 21474453?><pub-id pub-id-type="pmid">21474453</pub-id></mixed-citation>
      </ref>
      <ref id="B20">
        <label>20.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>R. G.</given-names></name>, <name name-style="western"><surname>Hayden</surname><given-names>M. S.</given-names></name>, and <name name-style="western"><surname>Ghosh</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>) <article-title>NF-ÎºB, inflammation, and metabolic disease</article-title>. <source>Cell Metab</source>. <volume>13</volume>, <fpage>11</fpage>â<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2010.12.008</pub-id>
<?supplied-pmid 21195345?><pub-id pub-id-type="pmid">21195345</pub-id></mixed-citation>
      </ref>
      <ref id="B21">
        <label>21.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rushe</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Silvian</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Bixler</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L. L.</given-names></name>, <name name-style="western"><surname>Cheung</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bowes</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Cuervo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Berkowitz</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Guckian</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Pellegrini</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Lugovskoy</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>) <article-title>Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site</article-title>. <source>Structure</source>
<volume>16</volume>, <fpage>798</fpage>â<lpage>808</lpage>
<pub-id pub-id-type="doi">10.1016/j.str.2008.02.012</pub-id>
<?supplied-pmid 18462684?><pub-id pub-id-type="pmid">18462684</pub-id></mixed-citation>
      </ref>
      <ref id="B22">
        <label>22.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Garzon</surname><given-names>J. I.</given-names></name>, <name name-style="western"><surname>LopÃ©z-Blanco</surname><given-names>J. R.</given-names></name>, <name name-style="western"><surname>Pons</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kovacs</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Abagyan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Fernandez-Recio</surname><given-names>J.</given-names></name>, and <name name-style="western"><surname>Chacon</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>) <article-title>FRODOCK: a new approach for fast rotational protein-protein docking</article-title>. <source>Bioinformatics</source>
<volume>25</volume>, <fpage>2544</fpage>â<lpage>2551</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btp447</pub-id>
<?supplied-pmid 19620099?><pub-id pub-id-type="pmid">19620099</pub-id></mixed-citation>
      </ref>
      <ref id="B23">
        <label>23.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>RamÃ­rez-Aportela</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>LÃ³pez-Blanco</surname><given-names>J. R.</given-names></name>, and <name name-style="western"><surname>ChacÃ³n</surname><given-names>P.</given-names></name></person-group> (<year>2016</year>) <article-title>FRODOCK 2.0: fast protein-protein docking server</article-title>. <source>Bioinformatics</source>
<volume>32</volume>, <fpage>2386</fpage>â<lpage>2388</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btw141</pub-id>
<?supplied-pmid 27153583?><pub-id pub-id-type="pmid">27153583</pub-id></mixed-citation>
      </ref>
      <ref id="B24">
        <label>24.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kozakov</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>D. R.</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>K. A.</given-names></name>, <name name-style="western"><surname>Padhorny</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Yueh</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Beglov</surname><given-names>D.</given-names></name>, and <name name-style="western"><surname>Vajda</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>) <article-title>The ClusPro web server for protein-protein docking</article-title>. <source>Nat. Protoc</source>. <volume>12</volume>, <fpage>255</fpage>â<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1038/nprot.2016.169,10.1038/nprot.2016.156</pub-id>
<?supplied-pmid 28079879?><pub-id pub-id-type="pmid">28079879</pub-id></mixed-citation>
      </ref>
      <ref id="B25">
        <label>25.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Comeau</surname><given-names>S. R.</given-names></name>, <name name-style="western"><surname>Gatchell</surname><given-names>D. W.</given-names></name>, <name name-style="western"><surname>Vajda</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Camacho</surname><given-names>C. J.</given-names></name></person-group> (<year>2004</year>) <article-title>ClusPro: a fully automated algorithm for protein-protein docking</article-title>. <source>Nucleic Acids Res</source>. <volume>32</volume>, <fpage>W96</fpage>â<lpage>99</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkh354</pub-id>
<?supplied-pmid 15215358?><pub-id pub-id-type="pmid">15215358</pub-id></mixed-citation>
      </ref>
      <ref id="B26">
        <label>26.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lyskov</surname><given-names>S.</given-names></name>, and <name name-style="western"><surname>Gray</surname><given-names>J. J.</given-names></name></person-group> (<year>2008</year>) <article-title>The RosettaDock server for local protein-protein docking</article-title>. <source>Nucleic Acids Res</source>. <volume>36</volume>, <fpage>W233</fpage>â<lpage>238</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn216</pub-id>
<?supplied-pmid 18442991?><pub-id pub-id-type="pmid">18442991</pub-id></mixed-citation>
      </ref>
      <ref id="B27">
        <label>27.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lyskov</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>F. C.</given-names></name>, <name name-style="western"><surname>ConchÃºir</surname><given-names>S. Ã.</given-names></name>, <name name-style="western"><surname>Der</surname><given-names>B. S.</given-names></name>, <name name-style="western"><surname>Drew</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kuroda</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Weitzner</surname><given-names>B. D.</given-names></name>, <name name-style="western"><surname>Renfrew</surname><given-names>P. D.</given-names></name>, <name name-style="western"><surname>Sripakdeevong</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Borgo</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Havranek</surname><given-names>J. J.</given-names></name>, <name name-style="western"><surname>Kuhlman</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Kortemme</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Bonneau</surname><given-names>R.</given-names></name>, <etal>et al</etal></person-group> (<year>2013</year>) <article-title>Serverification of molecular modeling applications: the Rosetta Online Server that Includes Everyone (ROSIE)</article-title>. <source>PLoS ONE</source>
<volume>8</volume>, <fpage>e63906</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0063906</pub-id>
<?supplied-pmid 23717507?><pub-id pub-id-type="pmid">23717507</pub-id></mixed-citation>
      </ref>
      <ref id="B28">
        <label>28.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hauenstein</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Kabaleeswaran</surname><given-names>V.</given-names></name>, and <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>) <article-title>Evidence for M1-Linked polyubiquitin-mediated conformational change in NEMO</article-title>. <source>J. Mol. Biol</source>. <volume>429</volume>, <fpage>3793</fpage>â<lpage>3800</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2017.10.026</pub-id>
<?supplied-pmid 29111346?><pub-id pub-id-type="pmid">29111346</pub-id></mixed-citation>
      </ref>
      <ref id="B29">
        <label>29.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polley</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D. B.</given-names></name>, <name name-style="western"><surname>Hauenstein</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Fusco</surname><given-names>A. J.</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Vu</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>SchrÃ¶felbauer</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hoffmann</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>I. M.</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>G.</given-names></name>, and <name name-style="western"><surname>Huxford</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>) <article-title>A structural basis for IÎºB kinase 2 activation via oligomerization-dependent trans auto-phosphorylation</article-title>. <source>PLoS Biol</source>. <volume>11</volume>, <fpage>e1001581</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pbio.1001581</pub-id>
<?supplied-pmid 23776406?><pub-id pub-id-type="pmid">23776406</pub-id></mixed-citation>
      </ref>
      <ref id="B30">
        <label>30.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Misquitta</surname><given-names>Y. R.</given-names></name>, <name name-style="western"><surname>Olland</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Kelleher</surname><given-names>K. S.</given-names></name>, <name name-style="western"><surname>Kriz</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>L. L.</given-names></name>, <name name-style="western"><surname>Stahl</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Mosyak</surname><given-names>L.</given-names></name></person-group> (<year>2013</year>) <article-title>Crystal structure of a human IÎºB kinase Î² asymmetric dimer</article-title>. <source>J. Biol. Chem</source>. <volume>288</volume>, <fpage>22758</fpage>â<lpage>22767</lpage><pub-id pub-id-type="pmid">23792959</pub-id></mixed-citation>
      </ref>
      <ref id="B31">
        <label>31.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huse</surname><given-names>M.</given-names></name>, and <name name-style="western"><surname>Kuriyan</surname><given-names>J.</given-names></name></person-group> (<year>2002</year>) <article-title>The conformational plasticity of protein kinases</article-title>. <source>Cell</source>
<volume>109</volume>, <fpage>275</fpage>â<lpage>282</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(02)00741-9</pub-id>
<?supplied-pmid 12015977?><pub-id pub-id-type="pmid">12015977</pub-id></mixed-citation>
      </ref>
      <ref id="B32">
        <label>32.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Polley</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Passos</surname><given-names>D. O.</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>D. B.</given-names></name>, <name name-style="western"><surname>Mulero</surname><given-names>M. C.</given-names></name>, <name name-style="western"><surname>Mazumder</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Biswas</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>I. M.</given-names></name>, <name name-style="western"><surname>Lyumkis</surname><given-names>D.</given-names></name>, and <name name-style="western"><surname>Ghosh</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>) <article-title>Structural basis for the activation of IKK1/Î±</article-title>. <source>Cell Rep</source>. <volume>17</volume>, <fpage>1907</fpage>â<lpage>1914</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.067</pub-id>
<?supplied-pmid 27851956?><pub-id pub-id-type="pmid">27851956</pub-id></mixed-citation>
      </ref>
      <ref id="B33">
        <label>33.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Vial</surname><given-names>S. C.</given-names></name>, <name name-style="western"><surname>Dedi</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Dunster</surname><given-names>N. J.</given-names></name>, and <name name-style="western"><surname>Cheetham</surname><given-names>G. M.</given-names></name></person-group> (<year>2005</year>) <article-title>Structural basis for the interaction of TAK1 kinase with its activating protein TAB1</article-title>. <source>J. Mol. Biol</source>. <volume>354</volume>, <fpage>1013</fpage>â<lpage>1020</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2005.09.098</pub-id>
<?supplied-pmid 16289117?><pub-id pub-id-type="pmid">16289117</pub-id></mixed-citation>
      </ref>
      <ref id="B34">
        <label>34.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>DiDonato</surname><given-names>J. A.</given-names></name>, <name name-style="western"><surname>Hayakawa</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Rothwarf</surname><given-names>D. M.</given-names></name>, <name name-style="western"><surname>Zandi</surname><given-names>E.</given-names></name>, and <name name-style="western"><surname>Karin</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>) <article-title>A cytokine-responsive IÎºB kinase that activates the transcription factor NF-ÎºB</article-title>. <source>Nature</source>
<volume>388</volume>, <fpage>548</fpage>â<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1038/41493</pub-id>
<?supplied-pmid 9252186?><pub-id pub-id-type="pmid">9252186</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>